Patents by Inventor Armin Hatzelmann

Armin Hatzelmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9340522
    Abstract: The compounds of Formula (I), are novel effective inhibitors of the type 4 phosphodiesterase.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: May 17, 2016
    Assignee: TAKEDA GMBH
    Inventors: Imre Schlemminger, Beate Schmidt, Dieter Flockerzi, Hermann Tenor, Christof Zitt, Armin Hatzelmann, Degenhard Marx, Clemens Braun, Raimund Kuelzer, Anke Heuser, Hans-Peter Kley, Geert Jan Sterk
  • Publication number: 20160108049
    Abstract: The compounds of formula (1), in which R1, R7, R8, R9, R10, R17, R18, R19, R20 and m have the meanings as given in the description, are novel effective inhibitors of type 4 and 5 phosphodiesterase.
    Type: Application
    Filed: December 3, 2015
    Publication date: April 21, 2016
    Inventors: Thomas STENGEL, Thomas MAIER, Alexander MANN, Josef STADLWIESER, Dieter FLOCKERZI, Andreas PAHL, Ewald BENEDIKTUS, Manuela HESSMANN, Tobias KANACHER, Ragna HUSSONG, Christof ZITT, Hans Christof HOLST, Rolf-Peter HUMMEL, Martin VIERTELHAUS, Hermann TENOR, Torsten DUNKERN, Armin HATZELMANN, Christian HESSLINGER
  • Patent number: 9090597
    Abstract: The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase useful in the treatment of psoriasis or atopic dermatitis.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: July 28, 2015
    Assignee: Takeda GmbH
    Inventors: Beate Schmidt, Christian Scheufler, Jürgen Volz, Martin Feth, Rolf-Peter Hummel, Armin Hatzelmann, Christof Zitt, Andrea Wohlsen, Degenhard Marx, Hans-Peter Kley, Deborah Ockert, Anke Heuser, Johannes A. M. Christiaans, Geert Jan Sterk, Wiro M. P. B. Menge
  • Patent number: 9018175
    Abstract: The compounds of Formula (1), in which A, R1, R2, R3 and R5 have the meanings as given in the description, are novel effective inhibitors of type 4 and 5 phosphodiesterase.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: April 28, 2015
    Assignee: Takeda GmbH
    Inventors: Dieter Flockerzi, Thomas Stengel, Alexander Mann, Harald Ohmer, Ulrich Kautz, Steffen Weinbrenner, Stefan Fischer, Christof Zitt, Armin Hatzelmann, Torsten Dunkern, Christian Hesslinger, Thomas Maier, Hermann Tenor, Clemens Braun, Raimund Külzer, Degenhard Marx
  • Publication number: 20140378509
    Abstract: The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase useful in the treatment of psoriasis or atopic dermatitis.
    Type: Application
    Filed: August 29, 2014
    Publication date: December 25, 2014
    Inventors: Beate SCHMIDT, Christian SCHEUFLER, Jürgen VOLZ, Martin FETH, Rolf-Peter HUMMEL, Armin HATZELMANN, Christof ZITT, Andrea WOHLSEN, Degenhard MARX, Hans-Peter KLEY, Deborah OCKERT, Anke HEUSER, Johannes A.M. CHRISTIAANS, Geert Jan STERK, Wiro M.P.B. MENGE
  • Patent number: 8865745
    Abstract: The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: October 21, 2014
    Assignee: Takeda GmbH
    Inventors: Beate Schmidt, Christian Scheufler, Juergen Volz, Martin Feth, Rolf-Peter Hummel, Armin Hatzelmann, Christof Zitt, Andrea Wohlsen, Degenhard Marx, Hans-Peter Kley, Deborah Ockert, Anke Heuser, Johannes A. M. Christiaans, Geert Jan Sterk, Wiro M. P. B. Menge
  • Publication number: 20140113877
    Abstract: The compounds of formula (1) in which A, X, R1, R2, R3 and R7 have the meanings as given in the description, are novel effective inhibitors of type 4 and type 5 phosphodiesterase.
    Type: Application
    Filed: June 12, 2012
    Publication date: April 24, 2014
    Applicant: Takeda GmbH
    Inventors: Dieter Flockerzi, Alexander Mann, Thomas Stengel, Harald Ohmer, Ulrich Kautz, Steffen Weinbrenner, Stefan Fischer, Hermann Tenor, Christof Zitt, Armin Hatzelmann, Torsten Dunkern, Christian Hesslinger, Clemens Braun, Ewald Benediktus, Andreas Pahl, Raimund Kuelzer, Degenhard Marx
  • Publication number: 20140112945
    Abstract: The compounds of formula (1) in which R1, R7, R8, R9, R10, R17, R18, R19, R20 and m have the meanings as given in the description, are novel effective inhibitors of type 4 and type 5 phosphodiesterase.
    Type: Application
    Filed: June 12, 2012
    Publication date: April 24, 2014
    Applicant: TAKEDA GmbH
    Inventors: Thomas Stengel, Thomas Maier, Alexander Mann, Josef Stadlwieser, Dieter Flockerzi, Andreas Pahl, Ewald Benediktus, Manuela Hessmann, Tobias Kanacher, Ragna Hussong, Christof Zitt, Hans Christof Holst, Rolf-Peter Hummel, Martin Viertelhaus, Hermann Tenor, Torsten Dunkern, Armin Hatzelmann, Christian Hesslinger
  • Publication number: 20140073672
    Abstract: The compounds of Formula (I), are novel effective inhibitors of the type 4 phosphodiesterase.
    Type: Application
    Filed: November 15, 2013
    Publication date: March 13, 2014
    Applicant: TAKEDA GMBH
    Inventors: Imre SCHLEMMINGER, Beate SCHMIDT, Dieter FLOCKERZI, Hermann TENOR, Christof ZITT, Armin HATZELMANN, Degenhard MARX, Clemens BRAUN, Raimund KUELZER, Anke HEUSER, Hans-Peter KLEY, Geert Jan STERK
  • Patent number: 8648100
    Abstract: The invention relates to the use of Roflumilast, Roflumilast N-Oxide or a pharmaceutically acceptable salt of either for the treatment of pulmonary hypertension. The invention additionally relates to the use of Roflumilast, Roflumilast N-oxide or a pharmaceutically acceptable salt of either in combination with a PDE5 inhibitor or a pharmaceutically acceptable salt thereof for the treatment of pulmonary hypertension.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: February 11, 2014
    Assignee: Takeda GmbH
    Inventors: Rolf Beume, Armin Hatzelmann, Degenhard Marx, Christian Schudt, Hermann Tenor, Saadia Eddahibi, Serge Adnot
  • Patent number: 8609848
    Abstract: The compounds of Formula (I), are novel effective inhibitors of the type 4 phosphodiesterase.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: December 17, 2013
    Assignee: Takeda GmbH
    Inventors: Imre Schlemminger, Beate Schmidt, Dieter Flockerzi, Hermann Tenor, Christof Zitt, Armin Hatzelmann, Degenhard Marx, Clemens Braun, Raimund Külzer, Anke Heuser, Hans-Peter Kley, Geert Jan Sterk
  • Publication number: 20130012544
    Abstract: The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Applicant: NYCOMED GMBH
    Inventors: Beate SCHMIDT, Christian SCHEUFLER, Jürgen VOLZ, Martin FETH, Rolf-Peter HUMMEL, Armin HATZELMANN, Christof ZITT, Andrea WOHLSEN, Degenhard MARX, Hans-Peter KLEY, Deborah OCKERT, Anke HEUSSR, Johannes A.M. CHRISTIAANS, Geert Jan STERK, Wiro M.P.B. MENGE
  • Publication number: 20120289474
    Abstract: The compounds of Formula (1), in which A, R1, R2, R3 and R5 have the meanings as given in the description, are novel effective inhibitors of type 4 and 5 phosphodiesterase.
    Type: Application
    Filed: December 15, 2010
    Publication date: November 15, 2012
    Applicant: NYCOMED GMBH
    Inventors: Dieter Flockerzi, Thomas Stengel, Alexander Mann, Harald Ohmer, Ulrich Kautz, Steffen Weinbrenner, Stefan Fischer, Christof Zitt, Armin Hatzelmann, Torsten Dunkern, Christian Hesslinger, Thomas Maier, Hermann Tenor, Clemens Braun, Raimund Külzer, Degenhard Marx
  • Patent number: 8304436
    Abstract: The compounds of a certain formula 1, in which R1, R7, R8, R9 and n have the meanings as given in the description, are novel effective inhibitors of the type 4 phosphodiesterase.
    Type: Grant
    Filed: May 14, 2008
    Date of Patent: November 6, 2012
    Assignee: Nycomed GmbH
    Inventors: Beate Schmidt, Christian Scheufler, Juergen Volz, Martin Feth, Rolf-Peter Hummel, Armin Hatzelmann, Christof Zitt, Andrea Wohlsen, Degenhard Marx, Hans-Peter Kley, Deborah Ockert, Anke Heuser, Johannes A. M. Christiaans, Geert Jan Sterk, Wiro M. P. B. Menge
  • Publication number: 20120196867
    Abstract: The claimed subject matter relates to pharmaceutical compositions comprising a PDE4 inhibitor and a PDE5 inhibitor and the treatment of a disease in which phosphodiesterase 4 (PDE4) and/or phosphodiesterase 5 (PDE5) is detrimental.
    Type: Application
    Filed: April 12, 2012
    Publication date: August 2, 2012
    Applicant: NYCOMED GMBH
    Inventors: Torsten DUNKERN, Armin HATZELMANN, Christian SCHUDT, Friedrich GRIMMINGER, Hossein Ardeschir GHOFRANI
  • Publication number: 20110218201
    Abstract: The compounds of Formula (I), are novel effective inhibitors of the type 4 phosphodiesterase.
    Type: Application
    Filed: November 12, 2009
    Publication date: September 8, 2011
    Applicant: NYCOMED GMBH
    Inventors: Imre Schlemminger, Beate Schmidt, Dieter Flockerzi, Hermann Tenor, Christof Zitt, Armin Hatzelmann, Degenhard Marx, Clemens Braun, Raimund Külzer, Anke Heuser, Hans-Peter Kley, Geert Jan Sterk
  • Patent number: 7838521
    Abstract: The compounds of formula I in which R1, R2 and R3 have the meanings as given in the description, are novel effective PDE4 inhibitors.
    Type: Grant
    Filed: September 5, 2005
    Date of Patent: November 23, 2010
    Assignee: NYCOMED GmbH
    Inventors: Dieter Flockerzi, Ulrich Kautz, Armin Hatzelmann, Christof Zitt, Andrea Wohlsen, Degenhard Marx, Hans-Peter Kley, Jens Christoffers, Anna Rosiak
  • Publication number: 20100234382
    Abstract: The invention relates to the combined administration of a PDE4 inhibitor and a PDE5 inhibitor for the treatment of a disease in which phosphodiesterase 4 (PDE4) and/or phosphodiesterase 5 (PDE5) is detrimental.
    Type: Application
    Filed: May 24, 2010
    Publication date: September 16, 2010
    Applicant: NYCOMED GMBH
    Inventors: Torsten DUNKERN, Armin HATZELMANN, Christian SCHUDT, Friedrich GRIMMINGER, Hossein Ardeschir GHOFRANI
  • Publication number: 20100120757
    Abstract: The compounds of a certain formula 1, in which R1, R7, R8, R9 and n have the meanings as given in the description, are novel effective inhibitors of the type 4 phosphodiesterase.
    Type: Application
    Filed: May 14, 2008
    Publication date: May 13, 2010
    Applicant: NYCOMED GmbH
    Inventors: Beate Schmidt, Christian Scheufler, Juergen Volz, Martin Feth, Rolf-Peter Hummel, Armin Hatzelmann, Christof Zitt, Andrea Wohlsen, Degenhard Marx, Hans-Peter Kley, Deborah Ockert, Anke Heuser, Johannes A.M. Christiaans, Geert Jan Sterk, Wiro M.P.B. Menge
  • Publication number: 20090239895
    Abstract: The compounds of formula I in which A, R1, R2 and R3 have the meanings as given in the description, are novel effective PDE4 inhibitors.
    Type: Application
    Filed: May 28, 2009
    Publication date: September 24, 2009
    Applicant: Nycomed GmbH
    Inventors: Dieter Flockerzi, Ulrich Kautz, Armin Hatzelmann, Christof Zitt, Andrea Wohlsen, Degenhard Marx, Hans-Peter Kley, Jens Christoffers, Anna Rosiak